Today: 1 February 2026
Subscribe
Browse Category

NASDAQ:BMRN News 19 December 2025 - 20 December 2025

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh…
20 December 2025
·····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters Because it’s a…
20 December 2025
·····
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage…
19 December 2025
····
1 2

Stock Market Today

  • Dynamic Active Canadian Bond ETF (DXBC:CA) Market Analysis and Trading Signals - Feb 2026
    February 1, 2026, 4:24 AM EST. On February 1, 2026, the Dynamic Active Canadian Bond ETF (DXBC:CA) received neutral ratings across short, mid, and long-term horizons according to AI-generated signals. The trading plan suggests a buy near $21.75 with a target of $21.98 and a stop-loss at $21.64, while a short position is recommended near $21.98 targeting $21.75 with a stop-loss at $22.09. These signals reflect cautious market positioning in fixed income assets, highlighting the ETF's current stability. Market participants should note the updated timestamp and utilize these AI-driven insights with consideration of overall bond market conditions.
Go toTop